Story
Postmenopausal Health
Last updated
In one pass Once you have gone 12 months in a row without a period, you are officially postmenopausal.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
What changes after menopause
Once you have gone 12 months in a row without a period, you are officially postmenopausal. This is not a stretch to be endured but a new baseline: estrogen no longer swings up and down; it settles at a low level and stays there for roughly the last third of your life.
One sentence is enough to understand what follows: this is a withdrawal, and it releases several brakes at once. Estrogen had been holding down several things. It restrains the crew that breaks down bone; it keeps the inner lining of blood vessels releasing a signal that relaxes them; it widens the temperature range in the brain before sweating starts; and it steers spare fat toward the skin of the hips and thighs. When estrogen withdraws, those hands let go together: bone loss speeds up, vessels stiffen, a little warmth sets off sweating, and fat moves toward the belly.
They look like four separate things, but they are four downstream effects of one withdrawal. This story takes them one at a time: bone, the heart and blood vessels, the genital area and the waist, hormone therapy, and regular check-ups. One thing should not wait: any vaginal bleeding after menopause needs a doctor right away; do not just watch it yourself.
One sentence is enough to understand what follows: this is a withdrawal, and it releases several brakes at once. Estrogen had been holding down several things. It restrains the crew that breaks down bone; it keeps the inner lining of blood vessels releasing a signal that relaxes them; it widens the temperature range in the brain before sweating starts; and it steers spare fat toward the skin of the hips and thighs. When estrogen withdraws, those hands let go together: bone loss speeds up, vessels stiffen, a little warmth sets off sweating, and fat moves toward the belly.
They look like four separate things, but they are four downstream effects of one withdrawal. This story takes them one at a time: bone, the heart and blood vessels, the genital area and the waist, hormone therapy, and regular check-ups. One thing should not wait: any vaginal bleeding after menopause needs a doctor right away; do not just watch it yourself.
Mechanism · Why swings hurt but a low level harms
Perimenopause is the 4–10 year transition before menopause: estrogen swings wildly and hot flashes come and go. It has its own story (see Perimenopause). This story starts after that.Not a symptom phase, but a new baseline
Perimenopause is about fluctuation; postmenopause is about settling at a low level. That means that among the symptoms people are told to wait out, some really do fade on their own (most hot flashes, for example), but others do not go away; they persist, or even worsen, as long as estrogen stays low (bone loss and genitourinary syndrome of menopause, for example). This is also how the two stories divide the work: this one does not repeat the transition, but explains how each body system resets once estrogen is gone for good.
Why fluctuation feels worse, yet a low level is more dangerous
One common explanation is that symptoms like hot flashes respond to the rate of change. As the hormone keeps falling, the brain's temperature-control center recalibrates again and again, so symptoms rise and fade; once the level has landed and stopped moving, the recalibration slowly finishes and most people's hot flashes fade on their own. That is the half of waiting it out that is actually true.
Bone, blood vessels, and urogenital tissue, by contrast, can be thought of as reading not the rate but the level. Every day they rely on estrogen to keep a routine repair pace: how much is taken down and how much put back, how tight the vessel wall is set, how often the lining turns over. Once the level drops and does not come back, these tissues stay on a slower repair pace, day after day. So they do not get waited out; they accumulate. That is why this story puts its weight on them.
The stance of this story
Postmenopause is not the beginning of decline, and it should not be used to frighten anyone. It is a stage of life you can actively manage: the risks in some systems do rise, but each one has clear things to monitor and levers you can pull. This site does not replace your doctor; it helps you understand the mechanism so you can make decisions together with your doctor, with judgment of your own.
Mechanism · How one hormone runs so many systems
A question tends to come up at this point: bone, blood vessels, body temperature, fat. These four look completely unrelated, so how can one hormone reach all of them?The answer is that estrogen works differently from many hormones.
Hormones such as insulin and adrenaline are water-soluble. They cannot enter the cell; they can only knock on a receptor on the cell surface, and a relay inside the cell carries the message in. Their effects come quickly and go quickly.Estrogen is a small fat-soluble molecule. The oily cell membrane hardly stops it; it passes straight through and finds its receptor inside the cell. The pair then moves into the nucleus, docks at particular places on the DNA, and changes which genes are copied into proteins, and how fast. (Estrogen also has a few rapid effects through receptors on the cell membrane, but its long-term influence runs mainly through this gene-rewriting route.)
In other words, estrogen is not issuing a single command; it is adjusting a whole batch of settings. And cells carrying this receptor are found all over the body: the cells that build and break down bone, the lining of blood vessels, the temperature-control neurons of the hypothalamus, fat cells, the lining of the vagina. Each has different settings being adjusted, so the same hormone seems to be doing unrelated things in different places.
That explains two things
Why the downstream effects of withdrawal are so scattered: estrogen did not affect many organs by the way. Those organs had already handed part of their day-to-day settings to the same signal. When the signal withdraws, each organ falls back to its own default, so the effects naturally look very different.Why "one bottle of supplements takes care of menopause" does not hold: what you would have to copy is not one reaction but a batch of settings spread across dozens of cell types. Any single nutrient can only restock the raw material for one of those chains (calcium and vitamin D restock bone's raw materials, for example); it cannot replace the layer that gives the orders. This does not mean nutrition is useless; it means that what nutrition can fix and what a hormone or a drug can fix were never the same job.
A side note: this change-the-settings way of working also explains why hormone therapy does not act the moment you take it. Copying genes, making proteins, and renewing tissue all take time, so whether the treatment is systemic or local, changes at the tissue level usually take weeks to show.
Chapter 2
Bone loss is fastest around menopause
Bone loss is not aging that starts at 70. It clusters in the years around the last period, and only after that settles into slower, ongoing loss. A multi-ethnic cohort of women (SWAN) measured at the lumbar spine and the femoral neck (the top of the thigh bone) falling by about 2% a year during those years, faster than before or after.
Bone is not a stone sitting still; every day part of it is taken down and rebuilt. The demolition crew is called osteoclasts and the building crew osteoblasts. Normally the two work at the same pace and bone mass holds steady. Estrogen's role here is to hold back the demolition crew: it makes the start-demolition signal a little weaker and the do-not-demolish signal a little stronger.
When estrogen withdraws, that hand lets go. Demolition speeds up first, building cannot keep up, and a little bone is lost each year. This stretch, when demolition outpaces building, is what is called the acceleration window. It shapes when to screen and when to act, because the window for prevention comes first and the consequences come later.
Bone is not a stone sitting still; every day part of it is taken down and rebuilt. The demolition crew is called osteoclasts and the building crew osteoblasts. Normally the two work at the same pace and bone mass holds steady. Estrogen's role here is to hold back the demolition crew: it makes the start-demolition signal a little weaker and the do-not-demolish signal a little stronger.
When estrogen withdraws, that hand lets go. Demolition speeds up first, building cannot keep up, and a little bone is lost each year. This stretch, when demolition outpaces building, is what is called the acceleration window. It shapes when to screen and when to act, because the window for prevention comes first and the consequences come later.
Mechanism · How the signal to break down bone is freed
(The osteoporosis story has a step-by-step demonstration of this mechanism; see Osteoporosis.)The bone surface holds a pool of osteoclast precursors waiting to be put to work. Osteoblasts, the bone builders, send them a start-demolition signal molecule (). It docks on a receptor on the precursor's surface, and several precursors fuse into one large cell with many nuclei: an osteoclast. The osteoclast presses onto the bone surface, seals off a small patch with its ruffled membrane like a suction cup, and pumps acid and protein-cutting enzymes into that sealed space. The acid dissolves the mineral and the enzymes cut the collagen fibers. A pit has been dug.
Osteoblasts also send out a second molecule (OPG). It looks like RANKL's receptor but is not attached to any cell; RANKL that runs into it is caught and never reaches the real receptor. So OPG is a decoy, a brake pad.
What estrogen does is press on both sides at once: it raises OPG and lowers RANKL.
With normal estrogen: more OPG and less RANKL, so osteoclasts cannot fill their ranks or live long, and building keeps pace with demolition.Once estrogen withdraws: RANKL becomes relatively more plentiful, osteoclasts are activated in large numbers and live longer, breakdown outpaces building, and bone is lost overall.
So what happens: pits are dug one after another, the crew filling them cannot keep up, and the first thing to break is the trabeculae, the thin struts inside bone that brace one another like a sponge. Once a strut is cut through, the remaining ones cannot restore the original structure, however thick they grow. That is why a small drop in can raise fracture risk a lot: what is lost is not just weight but structure.
One thing you can work out for yourself: any situation that makes RANKL relatively more plentiful replays the same chain: long-term glucocorticoids, long periods of bed rest, estrogen disappearing too early (early menopause, removal of the ovaries). The other way round, in daily life there are very few inputs that speed up the building side, and weight-bearing and strength training are the most reliable of them. That is why they come ahead of any supplement on this story's practical list.
Numbers · How fast the acceleration window really is
How fast the acceleration window is (Greendale and colleagues 2012, the SWAN cohort, published in JBMR)This multi-ethnic cohort tracked women's for 5 years before and 5 years after the final menstrual period (FMP):
Bone loss starts speeding up about 1 year before the final period and slows down only about 2 years after it, without stopping.During this transmenopause stretch, bone density at the lumbar spine and femoral neck falls by about 2% a year, clearly faster than before or after.In other words, the years around menopause are the fastest period of bone loss in a woman's life; it is not gradual.
A counterintuitive point: the final menstrual period is only named final in hindsight, after twelve more months without a period. So the acceleration window can only be seen after the fact; while you are in it, it has no name yet. This is not academic hair-splitting; it is this chapter's most practical inference: do not wait for confirmation before you start. Weight-bearing exercise, calcium and vitamin D, not smoking, and limiting alcohol should be in place before the window arrives, and none of them ever needed to wait for confirmation anyway.
Why this deserves serious attention
Fracture risk (especially of the vertebrae and hip) rises markedly after 65, but bone's capital was drained quickly during that window around 50.In older women, hip fracture is clearly associated with later disability and death; it is not just a fall.That is why the message do not miss this decade keeps coming back: the window for prevention comes first, and the consequences come later.
Clinical · When to screen, and daily protection
How to find out about your bones (screening) (USPSTF 2025)The US Preventive Services Task Force's 2025 update recommends routine screening for osteoporosis with in women aged 65 and older. It is a USPSTF grade B recommendation, meaning moderate certainty of a net benefit. DXA is a low-dose X-ray scan of and the preferred way to measure it.For postmenopausal women under 65 with risk factors (low body weight, a parent who broke a hip, smoking, heavy drinking, early menopause, long-term glucocorticoids), a clinical risk-assessment tool (such as FRAX, which estimates the risk of fracture over the next ten years from age, weight, family history, and other factors) is used to decide whether to screen earlier.
Practical basics (for everyone)
Calcium 1,000–1,200 mg a day, food first (this is the amount in US guidelines): milk, yogurt, tofu, small fish eaten with their bones, leafy greens. Supplements only fill the gap.Vitamin D kept sufficient (see Vitamin D): calcium needs it to be laid down in bone.Weight-bearing and strength training, 2–3 times a week: its effect on bone is more direct than any single supplement's.Do not smoke, and limit alcohol: both are linked with faster bone loss.
Why it has to be weight-bearing, not just any movement
Bone cells are buried in the bone matrix and cannot see or feel the outside world. They decide whether to reinforce by sensing strain. When muscle pulls on bone and the push back from the ground presses along the shaft, the fluid in bone's very fine channels is squeezed and flows a little; the buried bone cells feel that flow and signal the building side to do more work.
So the same word, exercise, pays off very differently. By this mechanism, swimming and cycling are excellent for the heart and lungs, but the water's buoyancy and the saddle carry the body's weight, the bone never feels that compressive force, and the return for bone density is much smaller. Walking, jogging, climbing stairs, and loaded squats are the language bone cells understand.
This also explains why long bed rest loses bone fastest: not because lying down is toxic, but because there is no strain input, and the message the bone cells keep receiving is this much bone is not needed here.
How treatment is tiered, how FRAX is used in decisions, and the details of bisphosphonates and denosumab are covered in full in the osteoporosis story (see Osteoporosis), including reading T-scores, FRAX thresholds, and the ladder of drugs. What this chapter needs to make clear is that the acceleration window falls around menopause, so decisions about screening and treatment need to move earlier too.
Chapter 3
Heart risk rises as estrogen falls
Before menopause, women have clearly lower rates of cardiovascular disease than men of the same age, and estrogen's protection of blood vessels is thought to be one important reason. After menopause that protection withdraws, and risk starts to climb, gradually closing in on men's over the next decade or more. A 2020 scientific statement from the American Heart Association treats the menopause transition as a stretch in which cardiovascular risk speeds up. This is not a vague "vessels wear out with age"; it is a change with a mechanism and a point in time.
The inside of every blood vessel is lined with a thin layer of endothelial cells, only one cell thick, and this layer decides how tight or relaxed the vessel is. It constantly releases a small gas molecule, nitric oxide (). NO seeps into the ring of smooth muscle under the lining and makes it relax, so the vessel widens; it also helps platelets slide past instead of sticking to the wall.
One of estrogen's jobs is to make the lining produce more NO. When estrogen withdraws, NO output drops: vessels respond more slowly to changing demands, stiffen along their length, and let fats burrow into the wall more easily.
The loss of this protection is real, but everything it touches falls on traditional risk factors you can manage: blood pressure, blood lipids, blood sugar, and lifestyle.
The inside of every blood vessel is lined with a thin layer of endothelial cells, only one cell thick, and this layer decides how tight or relaxed the vessel is. It constantly releases a small gas molecule, nitric oxide (). NO seeps into the ring of smooth muscle under the lining and makes it relax, so the vessel widens; it also helps platelets slide past instead of sticking to the wall.
One of estrogen's jobs is to make the lining produce more NO. When estrogen withdraws, NO output drops: vessels respond more slowly to changing demands, stiffen along their length, and let fats burrow into the wall more easily.
The loss of this protection is real, but everything it touches falls on traditional risk factors you can manage: blood pressure, blood lipids, blood sugar, and lifestyle.
Mechanism · The vessel lining one cell thick
What estrogen does in blood vessels (all reversed once it withdraws)It promotes the release of nitric oxide () from the vessel lining, keeping vessels relaxed and elastic.It shapes blood lipids, helping keep (low-density lipoprotein cholesterol, the so-called bad cholesterol) lower and (high-density lipoprotein cholesterol) higher.It has anti-inflammatory and antioxidant effects on the vessel wall.After it withdraws: the lining works less well, the lipid profile worsens, and arteries stiffen.
The first point, in full
When estrogen binds its receptor on an endothelial cell, it makes the enzyme that produces NO (nitric oxide synthase) more active. NO is a gas; once made, it spreads out, and within seconds it passes through the lining into the smooth muscle beneath and makes that muscle relax. That is what lets a vessel keep up with demand when you climb stairs, when cold makes it tighten, or when a surge of emotion hits.
With less NO, three things get worse at once:
Slower response: when blood flow increases, the vessel should widen with it; now it widens late and less. The flow-mediated dilation that clinicians measure is exactly this.Stiffer vessels: smooth muscle stays tense for longer and the wall's structure changes, so the vessel as a whole loses elasticity and systolic pressure is pushed up more easily.Plaque starts more easily: NO also keeps white blood cells from sticking to the wall and keeps smooth muscle from overgrowing. With less of it, oxidized LDL slips under the lining more easily and is swallowed by macrophages, turning them into foam cells. That is the starting point of atherosclerosis (see Cardiovascular System).
So what happens: this is not a vessel suddenly failing one day; it is the same vessel losing a little of its elastic reserve every day. It also explains something often misread: why blood pressure, blood lipids, and arterial stiffness all drift in the wrong direction together after menopause. They are not three unrelated pieces of bad news but three readings of one layer of cells that has changed state.
Evidence · Why the transition speeds up heart risk
The menopause transition is a point where cardiovascular risk speeds up (El Khoudary and colleagues 2020, American Heart Association scientific statement)The American Heart Association's 2020 scientific statement reviewed the evidence systematically. Its core conclusions:
A growing body of research supports an acceleration of cardiovascular risk during the menopause transition, not merely a steady rise with age.Unfavorable changes observed during the transition include rising and total cholesterol, more visceral fat, changes in vessel structure (a thicker inner wall of the carotid artery), and worsening trends in lipid metabolism and blood pressure.The statement stresses that the transition is a key window for early prevention: women's cardiovascular health should be monitored and managed from midlife, not after something has already happened.
What this means for you (you can act on it; no need to panic)
Blood pressure: measure it regularly and keep it on target (see Hypertension).Blood lipids: monitor LDL, and if needed discuss with your doctor whether a cholesterol-lowering drug such as a statin is warranted (see Cardiovascular System).Blood sugar and metabolism: watch your waist and insulin resistance (covered in detail in Changes that don't fade on their own).Lifestyle: a Mediterranean or DASH diet, regular aerobic exercise plus strength training, not smoking, and limiting alcohol. By the mechanism, these pay off more after menopause, because estrogen's free protection is gone.
Why exercise fits the mechanism especially well here
Every heartbeat pushes blood through the vessels, and as it flows over the lining it creates a drag along the wall (shear stress), which is one of the main triggers for the lining to start producing . Regular aerobic exercise is like daily overtime on this pathway, and it restores exactly the link that estrogen's withdrawal removed.
That is also why, for blood vessels, training sits closer to the mechanism than supplements: a supplement delivers raw materials, but what the lining lacks is not raw material; it is the signal to get to work.
Evidence · Can hormone therapy protect the heart?
You may have heard that estrogen protects the heart; that is the core of the controversy around the timing hypothesis for menopausal hormone therapy (). The short conclusion: started in the right timing window (early after menopause, before 60), MHT is neutral or slightly favorable for the heart and blood vessels; started many years after menopause, it should not be used to protect the heart. The full reappraisal of the WHI trial, and the two randomized trials KEEPS and ELITE, are covered in A fresh look at hormone therapy.Why such a window might exist (a mechanistic guess, not a verdict)
Estrogen's benefit to blood vessels runs through the lining, and that route needs the lining to still be working. Soon after menopause the vessel wall is mostly still healthy, and putting estrogen back is like reconnecting the line that produces . Many years after menopause, the wall often already carries mature plaque, and the drug is no longer acting on a healthy lining.
What must be said plainly: this is the explanation the hypothesis offers, not a directly proven cause. Age and years since menopause cannot be randomized, so a randomized trial that tests timing and nothing else does not strictly exist. The current support comes from two kinds of evidence: reanalyses split by age after the fact (the split was made afterwards, which is weaker than the original randomized comparison), and trials whose endpoint was vessel imaging (a stand-in measure, not heart attack or death itself).
So the rise in cardiovascular risk after menopause is a change with a clear mechanism, but it lands on traditional risk factors you can manage. Getting blood pressure, blood lipids, metabolism, and lifestyle under control is closer to the mechanism than agonizing over any heart-protecting supplement.
Chapter 4
Changes that don't fade on their own
Two kinds of change after menopause share one feature: they do not heal with time; they get worse. That is exactly why they are so easily neglected by people who try to wait them out.
The first is the urogenital area, which medicine calls genitourinary syndrome of menopause (GSM). The lining of the vagina and urethra relies on estrogen to stay thick, elastic, and moist. When estrogen withdraws, this tissue becomes thinner, more fragile, and drier, and dryness, burning, painful sex, urgency and frequency of urination, and repeated urinary tract infections tend to arrive together. The biggest difference from hot flashes is that hot flashes mostly fade by themselves, and this does not. Left untreated, it keeps getting worse.
The second is fat relocating. Estrogen used to steer spare fat under the skin of the hips and thighs. When that hand lets go, the same number of calories is more easily stored in the belly, among the organs. A thicker waist is not a matter of looks; it adds a metabolic organ that releases signals just upstream of the liver.
The good news is that both have clear, effective responses, provided you recognize them first.
The first is the urogenital area, which medicine calls genitourinary syndrome of menopause (GSM). The lining of the vagina and urethra relies on estrogen to stay thick, elastic, and moist. When estrogen withdraws, this tissue becomes thinner, more fragile, and drier, and dryness, burning, painful sex, urgency and frequency of urination, and repeated urinary tract infections tend to arrive together. The biggest difference from hot flashes is that hot flashes mostly fade by themselves, and this does not. Left untreated, it keeps getting worse.
The second is fat relocating. Estrogen used to steer spare fat under the skin of the hips and thighs. When that hand lets go, the same number of calories is more easily stored in the belly, among the organs. A thicker waist is not a matter of looks; it adds a metabolic organ that releases signals just upstream of the liver.
The good news is that both have clear, effective responses, provided you recognize them first.
Mechanism · Dryness and recurrent UTIs come from one chain
Genitourinary syndrome of menopause (GSM) (for the full treatment ladder, see Perimenopause)GSM, formerly called vulvovaginal atrophy, covers the whole urogenital system's response to low estrogen: vaginal dryness, burning, painful sex, repeated urinary tract infections, and urgency and frequency of urination.The key difference from hot flashes: hot flashes mostly fade over the years after the transition; GSM keeps getting worse without treatment, and the longer it goes on, the more the tissue changes.Mechanism: the lining of the vagina and urethra thins, collagen and elastin decline, vaginal pH rises, and the bacterial community changes.Badly undertreated: because it is embarrassing to raise, because people assume it is just aging, and because they do not know treatment exists.
The change in bacteria, in full
Estrogen makes the cells on the surface of the vaginal lining store glycogen. When those cells are shed normally, the glycogen becomes food for lactobacilli, which ferment it into lactic acid. That keeps the vagina slightly acidic, and other bacteria find it hard to take hold.
Once estrogen withdraws, the chain collapses link by link:
There are fewer surface cells and they turn over more slowly, so less glycogen is stored.The lactobacilli have less to eat, and their numbers fall.There is less lactic acid, and the pH rises.Bacteria that the acid used to hold down (including E. coli coming from the skin around the anus) take hold, and the opening of the urethra is right next door.
So dryness and repeated urinary tract infections are not two separate problems; they are the two ends of one chain. How E. coli sticks to the urinary lining has its own story (UTI and cranberry).
This also explains something that puzzles many people: why repeated antibiotics for urinary tract infections clear each episode but cannot stop the next one. Antibiotics kill the bacteria that have already taken hold; they do not make the ground acidic again. Local estrogen does exactly that second job; how it works, and why its risks differ from those of systemic treatment, get a page of their own in this chapter.
Clinical · What local estrogen does, and its limits
The core point (the GSM part of the perimenopause story goes into more detail): with local, low-dose vaginal estrogen, the estrogen level in the blood stays essentially within the postmenopausal range, so its risk profile is very different from systemic ; it is also not bound by systemic MHT's timing rule of starting within 10 years of menopause and before 60. It can be combined with pelvic-floor physical therapy.How effective is it? The guideline gives a judgment, not a percentage. The North American Menopause Society (NAMS) 2020 position statement says that low-dose vaginal estrogen, vaginal DHEA, systemic estrogen therapy, and ospemifene are all effective treatments for moderate to severe GSM. Note that it gives the judgment effective and no efficacy rate at all. So what to take from this page is that it is treatable, and putting up with it means choosing long-term discomfort, not a percentage.
One group has to take a different route: women with a history of breast cancer or an estrogen-sensitive tumor. The same NAMS 2020 statement is clear that current data are insufficient to confirm the safety of vaginal estrogen, vaginal DHEA, or ospemifene in women with breast cancer, and that GSM should be managed according to her own needs and her oncologist's advice. In other words, local treatment sidesteps systemic MHT's timing window, not the contraindication itself, and this is not a decision to make alone. For this group, hormone-free vaginal moisturizers, lubricants, and pelvic-floor physical therapy remain a safe first step.
Why local and systemic treatment differ so much
The drug is placed directly on the few layers of tissue that need it and is used up nearby by the cells there; very little actually enters the circulation. So the concerns that come with systemic hormones (clots, the breast, the age at starting) carry very different weight here. That safety margin comes from putting the drug in the right place, not from a small dose meaning a weak effect.
What it actually repairs
Local estrogen lets the vaginal lining thicken again, glycogen be stored again, the lactobacilli eat again, and the pH fall again. In other words, it does not smear on a lubricant to cover a symptom; it reconnects the bacterial chain from the start.
This mechanism also answers two common questions:
Why it takes weeks to work: thickening the lining and rebuilding the bacterial community both take time; it is not a painkiller that acts on the spot.Why things slowly slide back after you stop: what you removed is the signal that held that state, so the tissue returns to its default setting. That is not the drug failing to cure it; the low-estrogen premise never went away.
One sentence that must stay here: any vaginal bleeding after menopause is a red flag that needs a doctor right away; see What to check regularly. It is not the same thing as the dryness or small tears of GSM, so do not decide the cause yourself or just watch it.
Mechanism · Why fat moves from under the skin to the belly
The shift in body composition and metabolismEstrogen maintains a fat distribution under the skin (the pear shape). Once it withdraws, fat is redistributed to the abdomen and around the organs, shifting toward an apple shape.More visceral fat brings rising insulin resistance, and with it metabolic syndrome, type 2 diabetes, fatty liver, and cardiovascular risk all rise (see Type 2 Diabetes & Prediabetes / nafld / cardiovascular).A common source of confusion: I am eating the same and moving the same, yet my weight has gone up and my waist has clearly thickened. This part really is driven by a hormonal change; it is not a willpower problem.At the same time, muscle mass declines with age (sarcopenia; see Sarcopenia), and stacked on rising fat it becomes sarcopenic obesity: invisible on the scale, but the most damaging to how well the body functions.
Why the first point happens
Fat is not a bag for storage but a crowd of cells that take instructions, and fat cells in different places take different instructions.
Subcutaneous fat cells in the hips and thighs carry many estrogen receptors. There estrogen does two jobs: it makes fat easier to store and harder to call back out. As a result, surplus energy goes preferentially to the lower body; that is the pear shape.Visceral fat cells inside the abdomen are more sensitive to mobilizing signals such as adrenaline, break down fat more actively, and pour out free fatty acids at the slightest prompt.The key difference is where they drain: fatty acids released by subcutaneous fat enter the general circulation and are diluted along the way, while the veins of visceral fat drain straight into the portal vein, a pipe that leads specifically to the liver. The fatty acids and inflammatory signals poured out by visceral fat arrive at the liver's door at close to full strength.
Once estrogen withdraws, the hand that steered fat under the skin lets go, and a larger share of the same calorie surplus lands inside the abdomen. Following the chain from there:
More visceral fat makes the free fatty acids and inflammatory signals in the portal vein more concentrated; liver cells respond less to insulin, and the liver's sugar production (gluconeogenesis), which should switch off, does not; fasting blood sugar creeps up, so the pancreas has to release more insulin; and higher insulin pushes fat to keep being stored, closing the loop.
This is a widely cited explanation (the portal hypothesis) and it makes mechanistic sense, but how large a share of the fatty acids reaching the liver actually comes from visceral fat is still debated in research.
So you can work out three things yourself
Why watching your waist beats watching the scale: the scale weighs the whole body, while the risk in this chain comes mainly from that small area upstream of the portal vein. At the same weight, fat under the skin and fat among the organs are two completely different metabolic situations.Why strength training comes before supplements: muscle is the body's largest destination for sugar, and after training its sensitivity to insulin really does rise for a while. Sending sugar to muscle takes load off the liver and pancreas.Why the same diet builds more belly fat after menopause: what has changed is not how much you eat but where the same energy is sent. The switch that allocates it has moved. This is not a willpower problem, and it should not be tackled as one.
In practice · Managing body composition, and what not to buy
How to respond to the shift in body composition (levers that match the mechanism)Strength training (by the mechanism, the single measure with the highest return): keeping muscle keeps your resting metabolism and insulin sensitivity, and it helps prevent falls; 2–3 times a week.Protein at 1.2–1.6 g/kg a day (for people doing strength training): the lower end comes from the PROT-AGE expert group's recommendation for older adults over 65 who exercise (at least 1.2 g/kg a day); the upper end comes from Morton 2018's (its regression analysis), in which gains in muscle with resistance training level off at around 1.6 g/kg a day, and adding more brings no further return. Many people eat too little protein, and breakfast is especially likely to fall short (see Sarcopenia). People with chronic kidney disease should follow their kidney specialist's advice on protein rather than this range.Watch your waist, not just your weight: visceral fat is the core of the risk, and the scale will mislead you.A Mediterranean or DASH diet, plus regular aerobic exercise: these directly counter visceral fat and metabolic risk.
Why spreading protein evenly across meals is emphasized (and how far the evidence goes)
First, where the evidence stands: getting enough in total has guideline backing; how to split it across meals does not yet. PROT-AGE itself states that the evidence on timing is not yet strong enough for a specific recommendation. So the next paragraph is a mechanistic inference: worth following, but not a conclusion on the same level as the total.
Muscle building does not add up a day's protein into a single account. It works more like a machine that has to be switched on: the amino-acid level from a meal has to cross a threshold before the building signal opens, and once open it lasts a few hours and then falls back. A big piece of meat at dinner and only a bowl of rice porridge at breakfast means pressing the switch once all day; the total looks sufficient, but the time actually spent building is short. The older you are, the higher that threshold (this is called anabolic resistance), so the same serving of protein is more likely to fail to flip the switch after menopause. This is also one of the core points of the sarcopenia story.
Marketing traps
Big bottles of menopause-specific blends, and natural hormone-balancing, detox, anti-aging formulas: usually a mix of black cohosh, soy isoflavones, and assorted vitamins, with weak evidence for such as fractures and cardiovascular events, and for GSM.Compounded "bioidentical" hormones (compounded BHRT) from compounding pharmacies: NAMS has warned against them explicitly. Standard, approved already includes bioidentical options and is properly regulated (covered in detail in A fresh look at hormone therapy).
Why the word natural carries almost no information here
The in your body is natural; the estradiol a drug manufacturer makes is the same molecule, looks for the same receptor inside the cell, and the molecule itself cannot tell where it came from. What really decides safety is four other things: the dose, the route into the body, your own risk profile, and whether a regulator is watching that batch of the drug. Compounding pharmacies are the least constrained on exactly these four: the actual content can vary from batch to batch, and there is no standard label or monitoring of side effects.
After menopause some things resolve on their own (most hot flashes) and some do not (GSM, bone loss, the shift in body composition). Recognizing and treating early the part that does not resolve is this story's most practical lesson. GSM is safe to treat, so do not put up with it; the shift in body composition responds to strength training, protein, and watching your waist, not to supplements.
Chapter 5
A fresh look at hormone therapy
Menopausal hormone therapy (, formerly often called HRT) is the most misunderstood topic in menopause medicine. The aim of this chapter is neither to demonize it nor to oversell it, but to give you an honest framework you can take into a conversation with your doctor.
The real keyword here is not whether to use it but when to start.
The reason is simple. The large trial (WHI) that caused hormone prescriptions to drop sharply more than twenty years ago mainly enrolled women who were already many years past menopause, on average more than ten years older than women just reaching it. Applying their results directly to someone whose periods have just stopped and whose blood vessels are still mostly healthy is the root of the misreading. When the results were later re-split by age at the start of treatment, the picture looked very different: the earlier treatment starts, the more the balance tilts toward benefit; the later it starts, the more it tilts toward risk. This is called the timing hypothesis; several lines of evidence support it, but it is still a hypothesis.
The full choice of formulations, the absolute risk figures, and the two randomized trials KEEPS and ELITE are covered in the MHT section of the perimenopause story (see Perimenopause). This chapter covers three things: how the misreading happened, what the timing hypothesis actually says, and what the absolute numbers look like.
The real keyword here is not whether to use it but when to start.
The reason is simple. The large trial (WHI) that caused hormone prescriptions to drop sharply more than twenty years ago mainly enrolled women who were already many years past menopause, on average more than ten years older than women just reaching it. Applying their results directly to someone whose periods have just stopped and whose blood vessels are still mostly healthy is the root of the misreading. When the results were later re-split by age at the start of treatment, the picture looked very different: the earlier treatment starts, the more the balance tilts toward benefit; the later it starts, the more it tilts toward risk. This is called the timing hypothesis; several lines of evidence support it, but it is still a hypothesis.
The full choice of formulations, the absolute risk figures, and the two randomized trials KEEPS and ELITE are covered in the MHT section of the perimenopause story (see Perimenopause). This chapter covers three things: how the misreading happened, what the timing hypothesis actually says, and what the absolute numbers look like.
Background · How the WHI trial was misread
The misreading of WHI 2002, and the twenty-year shadow it cast (Rossouw and colleagues 2002)In 2002 the estrogen-plus-progestin (E+P) arm of the WHI trial was stopped early. The headlines said hormone therapy raises breast cancer and heart attacks, and hormone prescriptions in the United States then fell sharply.The overlooked details: WHI participants were 63 on average, many were more than 10 years past menopause, and they took one particular combination, conjugated equine estrogens plus medroxyprogesterone acetate.Applying results from older women long past menopause directly to a 50-year-old woman who has just reached menopause is the root of the misreading.
Why this misreading has been so hard to correct
The trial itself did not say anything wrong. It reported what it measured in the people it enrolled. The distortion happened in two later steps:
The average was read as everyone: an average effect measured in one age group was read as true for any woman.One particular drug combination was read as the whole class of treatment: that arm used estrogen from a particular source and a particular progestin, yet the conclusion was applied to every estrogen and every route.
Neither step requires anyone to lie. It only takes moving a conclusion with very specific conditions onto a reader whose conditions differ.
This is also why this site keeps explaining mechanisms: people who remember only a conclusion have no way of judging it when the conclusion is updated, while people who understand in whom, with which drug, and when it was measured are able to judge whether it applies to them.
Evidence · What the timing hypothesis says, and does not
The timing hypothesis: risks and benefits depend on age and years since menopause at the start (Manson and colleagues 2017, JAMA)This paper pooled the two WHI randomized trials and followed the women for 18 years. Start with the paper's own conclusion: over 18 years of cumulative follow-up, hormone therapy did not change all-cause mortality ( 0.99, 95% 0.94–1.03), cardiovascular mortality (HR 1.00, 95% confidence interval 0.92–1.08), or cancer mortality. The authors' words are not associated. HR is the hazard ratio; 1 means no difference between the groups.
Split by age at the start (an analysis planned in advance):
Started at 50–59: during the years the study drugs were taken, mortality was lower than on placebo (HR 0.69, 95% confidence interval 0.51–0.94); over the full 18 years of follow-up, the difference was no longer significant (HR 0.89, 95% confidence interval 0.79–1.01).Started at 60–69: no significant difference in either period.Started at 70 or older: no significant difference in either period.Comparing the 50–59 group with the group aged 70 and older, the ratio of their nominal HRs during treatment was 0.61 (95% confidence interval 0.43–0.87); in other words, the younger the age, the more the balance tilts to the favorable side.
So the support this paper gives the timing hypothesis is a bounded statement: a relative difference between the younger and older groups exists, and the 50–59 group really did have lower mortality during the treatment years, but that difference did not stay significant over long-term follow-up, and overall hormone therapy was not associated with mortality. These numbers are not a reason to take to live longer, and not a reason to say it can never be used after 60. The indication for MHT is symptoms (see below); the timing window shifts the balance of risks and benefits.
An easy misreading: you may see the 50–59 group reported elsewhere as HR 0.79-0.91. That does not match the original paper. In the paper, this group's HR over cumulative follow-up was 0.89 with a 95% confidence interval of 0.79–1.01, whose upper end crosses 1, meaning it was not significant. When an interval is written as an HR, or its upper end is miscopied, what gets erased is precisely the fact that it was not significant.
Why such a window might exist, mechanistically
Estrogen's benefit to blood vessels runs through the lining (see Heart risk rises as estrogen falls), and that route needs the lining to still be working. Soon after menopause the vessel wall is mostly still healthy, and putting estrogen back is like reconnecting the line that produces nitric oxide. Many years after menopause, the wall often already carries mature plaque; estrogen added at that point meets different tissue and may even affect the stability of the plaque itself.
Honesty is required here
The paragraph above is the hypothesis's explanation, not a directly proven cause. Age and years since menopause cannot be randomized, so a randomized trial that tests only timing does not strictly exist. Current support comes from two kinds of evidence, each with a weak spot:
Reanalyses split by age after the fact: the split was made afterwards and each group becomes smaller, which is weaker than the original randomized comparison.Trials whose endpoint was vessel imaging: the endpoint is a stand-in measure (such as the thickness of the artery wall), not heart attack or death itself.
So the accurate statement is: the timing hypothesis is supported by several independent lines of evidence, and it is still a hypothesis.
That is enough to support a clinical recommendation (do not start systemic MHT many years after menopause in order to protect the heart), but not enough to support a slogan (start early and it will protect your heart). The distance between those two sentences is the weight of how far the evidence actually goes.
Clinical · What the guideline says, and two inferences
The current consensus in the NAMS 2022 position statement (NAMS 2022)is the first-line treatment for moderate to severe vasomotor symptoms (hot flashes and night sweats).Who it suits: women who are healthy, under 60, within 10 years of menopause, and without absolute contraindications.Absolute contraindications: a history of breast cancer, estrogen-sensitive tumors, severe liver disease, unexplained vaginal bleeding, active venous thromboembolism (VTE, blood clots in the veins), stroke, and heart attack (myocardial infarction, ).With a uterus: estrogen plus a progestogen (to protect the lining of the uterus); without a uterus: estrogen alone.Form: through the skin (patch or gel) carries a lower risk of venous clots than by mouth, because it avoids the liver's first-pass effect.
Why a uterus means a progestogen must be added
Estrogen drives the lining of the uterus to thicken; that is normally the first half of a menstrual cycle preparing for implantation. In a normal cycle, progesterone takes over in the second half, turns the lining into its secretory phase, and it is then shed as the hormones withdraw. Estrogen alone, without a progestogen, leaves the lining stuck in a grow-but-never-shed state; over time the risk of overgrowth and cancer rises. So the progestogen here is not an accessory; it is the brake. Women who have had a hysterectomy (surgery to take out the uterus) do not need that brake and can take estrogen alone.
Why patches and gels carry a lower clot risk than pills
A drug taken by mouth is absorbed from the gut and goes to the liver first; this is called the first-pass effect. And the liver is where clotting factors are made: a concentrated surge of estrogen passing through it pushes up the production of clotting-related proteins. Absorption through the skin skips that stop; the drug enters the general circulation first and is already diluted by the time it reaches the liver. At the same blood level, the stimulus the liver feels is completely different.
An inference you can reuse: whenever you meet the same molecule given by different routes, first ask: where is its first stop? That explains not only MHT patches versus pills but also why the local vaginal estrogen covered in Changes that don't fade on their own has such a different risk profile.
Numbers · Read breast-cancer risk in absolute figures
Breast cancer risk: read it in absolute numbers, and do not be frightened by (Chlebowski and colleagues 2020, JAMA)By the WHI figures, 5 years of estrogen plus progestin adds roughly 4–5 breast cancers per 1,000 women. The +26% relative risk WHI first reported sounds frightening, but the absolute increase is only about 0.4–0.5%, an increase often compared in size with those that smoking, moderate drinking, or obesity each bring.Long-term follow-up (a median of more than 20 years): in the estrogen-plus-progestin group, breast cancer incidence rose but breast cancer deaths did not rise significantly; in the estrogen-only group (women without a uterus), both breast cancer incidence and deaths actually fell.
Why relative risk misleads so easily
Relative risk answers how many times the original rate, while absolute risk answers how many extra people. With the same data, when the starting rate is small, the first can sound alarming while the second is actually small. So the first question to ask of any percentage is always: a percentage of what, and what is the starting rate?
Risk up by a quarter and four to five more per thousand describe the same fact. Both sentences are true, but the pictures they create in the mind are worlds apart, and the decision you have to make should rest on the second.
Why the estrogen-only group went the other way
This is the half of WHI that is often ignored. It suggests that what happens in the breast is more likely tied to the progestin than to estrogen itself. It is also a reminder that is not one drug but a family of regimens: which estrogen, whether a progestogen is added, which one, and by which route can all change the conclusion.
So the next time you hear that hormone therapy causes cancer, three follow-up questions are worth asking: which combination? started at what age? an increase in cases or in deaths? Skip one and the answer may have nothing to do with your situation.
Clinical · How to think about hormone therapy now
How to think about after menopause (the honest conclusion)If moderate to severe hot flashes bother you, you are within the timing window, and you have no contraindications: MHT is a first-line treatment and worth discussing seriously.Starting systemic MHT many years after menopause only to slow aging, protect the heart, or prevent osteoporosis: not recommended; the timing window has passed and the balance of risks is different.If you have contraindications, or would rather not use hormones: non-hormonal options do work, and they have a guideline of their own. The NAMS 2023 nonhormone therapy position statement (a separate document from the hormone statement above) recommends for hot flashes: and , two classes of antidepressants (such as paroxetine and venlafaxine), gabapentin, fezolinetant (a new non-hormonal drug that acts on the brain's temperature-control center, approved in 2023; its phase 3 trial is SKYLIGHT 2), and cognitive behavioral therapy and clinical hypnosis, all rated Level I in NAMS's own evidence scale (consistent, good-quality evidence); oxybutynin is rated Level I-II; clonidine is not recommended. For bone, see the osteoporosis story.For GSM: local vaginal estrogen is not bound by the timing window, but note that it is not an exception to the contraindications. If you have a history of breast cancer, whether to use it should be decided together with your oncologist (see Changes that don't fade on their own).If periods stopped before 40 (premature ovarian insufficiency, POI): this is a different matter. Hormone replacement until the age of natural menopause (about 51) is strongly recommended; without it, low-estrogen aging begins early.
MHT is not a yes-or-no question of whether to use it; it is a decision that weighs, point by point, your age, years since menopause, symptoms, and risk profile. This site does not replace your doctor; it helps you understand the timing hypothesis and the absolute numbers so you can make the decision together with your doctor, with judgment of your own.
nams-2023-nonhormone-positionlederman-2023-skylight-2
Chapter 6
What to check regularly
The core of staying healthy after menopause is not some miracle pill; it is watching the right few measures and pulling the right few levers. Here are the changes across the earlier systems gathered into one list:
What to monitor regularly (check with your doctor how often)
Blood pressure: the most modifiable part of the rise in cardiovascular risk; measure it regularly (see Hypertension).Blood lipids: monitor , , and . Lipids often worsen during the transition; if needed, discuss with your doctor whether you need a statin (see Cardiovascular System).Blood glucose and (HbA1c, which reflects average blood sugar over the past 2–3 months): more visceral fat pushes insulin resistance up, so keep an eye on glucose metabolism (see Type 2 Diabetes & Prediabetes). by : routinely from 65, and earlier for postmenopausal women with risk factors (USPSTF 2025; covered in detail in the bone chapter).Vitamin D status: keep it sufficient to support calcium absorption and bone health (see Vitamin D).Waist and body composition: these reflect visceral fat and metabolic risk better than the scale.Routine screening: breast, cervical, and other screening as guidelines advise. Any vaginal bleeding after menopause needs a doctor right away (this is a real red flag; do not put it off).
What to monitor regularly (check with your doctor how often)
Blood pressure: the most modifiable part of the rise in cardiovascular risk; measure it regularly (see Hypertension).Blood lipids: monitor , , and . Lipids often worsen during the transition; if needed, discuss with your doctor whether you need a statin (see Cardiovascular System).Blood glucose and (HbA1c, which reflects average blood sugar over the past 2–3 months): more visceral fat pushes insulin resistance up, so keep an eye on glucose metabolism (see Type 2 Diabetes & Prediabetes). by : routinely from 65, and earlier for postmenopausal women with risk factors (USPSTF 2025; covered in detail in the bone chapter).Vitamin D status: keep it sufficient to support calcium absorption and bone health (see Vitamin D).Waist and body composition: these reflect visceral fat and metabolic risk better than the scale.Routine screening: breast, cervical, and other screening as guidelines advise. Any vaginal bleeding after menopause needs a doctor right away (this is a real red flag; do not put it off).
In practice · Why strength training comes first
Levers to pull for the long term (matched to the mechanism, ranked by return)Strength training, 2–3 times a week: protects bone and muscle, improves insulin sensitivity, and prevents falls, all at once (see Sarcopenia).Regular aerobic exercise plus a Mediterranean or DASH diet: counters cardiovascular and metabolic risk.Calcium (food first) plus vitamin D: the nutritional foundation for bone, without relying on high-dose supplements.Protein at 1.2–1.6 g/kg (for people doing strength training): maintains muscle and the bone matrix. The lower end comes from PROT-AGE's recommendation for people over 65 who exercise, the upper end from the plateau in training gains that Morton 2018 found. Spread it across meals where you can, but the evidence for splitting is weaker than for the total; people with chronic kidney disease should follow their kidney specialist's advice.Not smoking, limiting alcohol, and regular sleep: three basics with a very high return (for changes in sleep structure, see Sleep Architecture & Sleep Debt).
Why strength training comes first, not some supplement
Go back to the thread at the start of this story: the withdrawal of estrogen released its hold on bone, blood vessels, body temperature, and fat distribution. A single session of strength training works on three of these at once:
Bone: the strain created when muscle pulls on bone is the main input bone cells use to decide whether to reinforce; it is the language bone understands best.Metabolism: muscle is the body's largest destination for sugar, and after training its sensitivity to insulin really does rise for a while, taking load off the liver and pancreas.Function: strength and balance decide whether you fall, while only decides whether a fall breaks something. Both need attention, but the first is the one most often forgotten.
No single supplement covers all three at once. This does not mean supplements are useless; it is a question of order. A supplement delivers raw materials, while training issues the instruction whether to use those materials. Stock the materials without issuing the instruction and bone and muscle will not strengthen on their own, which is also why calcium alone rarely buys bone density.
The lever most often skipped: sleep
After menopause, sleep often becomes lighter and more broken. In sleep-restriction experiments, short sleep does several bad things at once: it raises insulin resistance the next day and amplifies how strongly pain and discomfort are felt; on top of that, hot flashes that could have been slept through are more likely to wake you. Sleep interlocks with body composition, mood, and symptoms; it is not just poor sleep (see Sleep Architecture & Sleep Debt / insomnia).
How to use this list: do not start everything at once. Pick the lever you most lack right now, let it settle into a habit, then add the next. This story is about the last third of a life; the contest was never about how much you did in three months.
Background · Related stories to read next
What else to read: postmenopause is where several systems meetThe transition itself: hot flashes and the temperature-control neurons behind them, how it is diagnosed, the GSM treatment ladder, and the full numbers; see Perimenopause. It is this story's prequel.T-scores, FRAX, and the ladder of osteoporosis drugs, the deep dive behind this story's bone chapter: see Osteoporosis.The mechanisms of the vessel lining, blood lipids, and atherosclerosis: see Cardiovascular System.Managing blood pressure: see Hypertension.The metabolic risks that follow rising visceral fat: see Type 2 Diabetes & Prediabetes; fatty liver (metabolic dysfunction-associated steatotic liver disease, ) has its own story.Muscle loss, sarcopenic obesity, and strength training: see Sarcopenia.Changes in sleep structure and how insomnia is handled: see Sleep Architecture & Sleep Debt; insomnia has its own story (Insomnia).Stress and the hormonal transition amplifying each other: Chronic Stress · the Axis.
A reading order for postmenopausal women
1. This story: understand the long-term low-estrogen state and the shifts across systems.
2. Osteoporosis: the bone-loss window, and whether you need medication.
3. Sarcopenia: the baseline of strength training and protein.
4. Heart and blood pressure: how to monitor cardiovascular risk.
5. Perimenopause: if you still have hot flashes or are considering MHT, the full decision.
6. Sleep: if your sleep has become lighter and more broken.
Postmenopause is a stage of life you can actively manage, not a passive wait for decline. Estrogen's withdrawal raises the risk in several systems, but each one has clear measures to watch and levers that match the mechanism: watch the right measures, pull the right levers, and when MHT is appropriate, decide with your doctor within the timing window. Know what happens and why, and you will neither panic nor be taken in by anti-aging miracle cures. This site does not replace a doctor; any persistent or unusual symptom deserves a medical assessment.
References · 13
- Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. The Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. 10.1210/jc.2011-3362
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture; treatment should be individualised and periodically re-evaluated; for women younger than 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favourable for bothersome vasomotor symptoms and prevention of bone loss (abstract, PMID 35797481). 10.1097/GME.0000000000002028
- Greendale, G. A., Sowers, M., Han, W., Huang, M. H., Finkelstein, J. S., Crandall, C. J., Lee, J. S., & Karlamangla, A. S. (2012). Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of Bone and Mineral Research, 27(1), 111-118. SWAN: BMD loss began about 1 year before the final menstrual period and slowed, without stopping, 2 years after it, at both lumbar spine and femoral neck; loss was fastest from 1 year before to 2 years after (the transmenopause). Of the cumulative 10-year loss, 7.38% of 10.6% at the spine and 5.8% of 9.1% at the femoral neck occurred during the transmenopause; higher BMI and African American heritage were linked to slower loss, Japanese and Chinese ancestry to faster loss (abstract, PMID 21976317). 10.1002/jbmr.534
- US Preventive Services Task Force; Nicholson, W. K., Silverstein, M., Wong, J. B., et al. (2025). Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA, 333(6), 498-508. 10.1001/jama.2024.27154
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 25(10), 2359-2381. 10.1007/s00198-014-2794-2
- El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., & Allison, M. A. (2020). Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation, 142(25), e506-e532. 10.1161/CIR.0000000000000912
- The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. (2020). Menopause, 27(9), 976-992. 10.1097/GME.0000000000001609
- Portman, D. J., & Gass, M. L. S. (2014). Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from ISSWSH and NAMS. Menopause, 21(10), 1063-1068. 10.1097/GME.0000000000000329
- Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., et al. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: PROT-AGE Study Group. JAMDA, 14(8), 542-559. 10.1016/j.jamda.2013.05.021
- Morton, R. W., et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine, 52(6), 376–384. 49 RCTs, 1,863 participants, resistance training of 6 weeks or more. Protein supplementation added 2.49 kg to 1RM and 0.30 kg to fat-free mass; the effect fell with age and was larger in trained people. Break point for FFM gains at 1.62 g/kg/day (95% CI 1.03-2.20; 42 study arms, 723 participants; the biphasic model was not statistically significant, p = 0.079); given the CI, the authors say ~2.2 g/kg/day may be prudent for those maximising gains; timing, post-exercise dose and source play a minor if any role; they cite per-dose MPS break points of 0.24 (younger) and 0.40 g/kg (older). One author reports grant support from the US National Dairy Council (abstract and full text, PMC5867436). 10.1136/bjsports-2017-097608
- Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. 10.1001/jama.288.3.321
- Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA, 318(10), 927-938. 27,347 women, 18-year cumulative follow-up. Pooled all-cause mortality HR 0.99 (0.94-1.03). Women aged 50-59: HR 0.69 (0.51-0.94) during the intervention phase; cumulative HR 0.89 (0.79-1.01), trend by age no longer significant (full text, Results). 10.1001/jama.2017.11217
- Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA, 324(4), 369-380. 10.1001/jama.2020.9482